Male osteoporosis and androgenic therapy: From testosterone to SARMs

Clinical Cases in Mineral and Bone Metabolism

Volumn 6, Issue 3, 2009, Pages 229-233

  Cilotti, Antonio ^a   Falchetti, Alberto ^a  

^a University Hospital of Careggi   (Italy)

Author keywords

Andtogen; Hypogonadism; Male osteoporosis; Sarm; Testosterone

Indexed keywords

ANTIANDROGEN; ANTICONVULSIVE AGENT; BICALUTAMIDE; CYPROTERONE ACETATE; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; GONADORELIN DERIVATIVE; MK 2866; NILUTAMIDE; OSTARINE; QUINOLINE DERIVATIVE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SPIRONOLACTONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; BONE MINERALIZATION; CACHEXIA; CANCELLOUS BONE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORTICAL BONE; DRUG IMPLANT; DRUG PELLET; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; GEL; HUMAN; HYPOGONADISM; LIFE EXPECTANCY; MALE; MALE OSTEOPOROSIS; OSTEOPOROSIS; PERIOSTEUM; SHORT SURVEY; SOCIAL PROBLEM; TRANSDERMAL PATCH;

EID: 76749132220     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (46)

1. Melton LJ 3rd, Chrischilles EA. Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res. 1992;7: 1005-10.
2. Center JR, Nguyen TV. Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-82.
3. Seeman E Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab. 2001 ;86:4576-84.
4. Singer BR. McLauchlan GJ. Robinson CM, et al. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br. 1998;80:243-48.
5. Haentjens P. Johnell O. Kanis JA, et al. Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res. 2004;19:1933-44.
6. Cuddihy MT. Gabriel SE. Crowson CS. et al. Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int. 1999;9:469-75.
7. Center JR, Nguyen TV. Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: on observational study. Lancet. 1999;353:878-82.
8. Faulkner KG. Orwoll E. Implications in the use of T scores for the diagnosis of osteoporosis in men. J Clin Densitom. 2002;5:S19-27.
9. Binkley NC. Schmeer P. Wasnich RD. et al. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom. 2002:5:219-27.
10. Leslie WD. Adler RA. El-Hajj Fuleihan G. et al. Application ot the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD official positions. J Clin Densitom. 2006;9:22-30.
11. Van Staa TP. Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-00.
12. Kanis JA. Johansson H. Johnell O et al. Alcohol intake as a risk factor for fracture. Osteoporosis International. 2005;16:737-42.
13. George A. Tracy JK, Meyer WA. Flores RH, Wilson PD, Hochberg MC. Racial differences in bone mineral density in older men. J Bone Miner Res. 20O3 Dec;18.12:2238-44.
14. Schwartz AV. Kelsey JL. Maggi S. Tuttleman M. Ho SC. Jonsson PV, Poor G. Sisson de Castro JA. Xu L. Matkin CC, Nelson LM, Heyse SP. International variation in the incidence of hip fractures: Cross-national project on osteoporosis for the world health organization proram for research aging. Osteoporos Int. 1999;9:242-53.
15. Mittan D, Lee S, Miller E, Perez RC. Basler JW. Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656-61.
16. Mellström D. Johnell O. Ljunggren O. et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. 2006;21:529-35.
17. Kaufman JM. Goemaere S. Osteoporosis in men. Best Practice & Research Clinical Endocrinology & Metabolism. 2008:5:787-12.
18. Jackson JA, Kleerekoper M. Parfitt AM. Rao DS. Villanueva AR, Frame B Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab. 1987;65:53-58.
19. Leder BZ. Finkelstein JS Gonadal steroids and the skeleton in men. Clinical aspects. In: Orwoll ES. Bliziotes M. eds. Osteoporosis. Pathophysiology and clinical management. Totowa. NJ: Humana Press; 2002:393-411.
20. Riggs BL. Khosla S. Melton U. Sex steroids and the constructionand conservation of the adult skeleton. Endocr Rev 2002;23: 279-302.
21. Kousteni S. Belltio T. Plotkin LI. O'Brien CA. Bodenner DL. Han L Han K. Di Gregorio GB. Katzenellenbogen JA. Katzenellenbogen BS, Roberson PK. Weinstein RS. Jilka RL Manolagas SC. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001;104:719-30.
22. Vanderschueren D. Vandenput L. Boonen S et al. Androgens and bone. Endocrine Reviews 2004;25:389-25.
23. Kousteni S. Han L, Chen JR. Almeida M. Plotkin LI, Bellido T. Manolagas SC. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest. 2003;111:1651-64
24. Brinkmann AO. Faber PW. van Rooij HC, et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem. 1989;34:307-10.
25. Khorasanizadeh S. Rastinejad F. Nuclear-receptor interactions onDNA-responseelements. Trends Biochem Sci. 2001;26:384-90.
26. Matsumoto T. Shiina H. Kawano H. Sato T. Kato S. Androgen receptor functions in male and female physiology. J Steroid Biochem Mol Biol. 2008;109:236-41.
27. Falkenstein E. Tillmann HC. Christ M. Feuring M. Wehling M. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev. 2000;52:513-56.
28. Keenan BS. Richards GE. Ponder SW. Dallas JS, Nagamani M, Smith ER. Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-l in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab. 1993;76:996-01.
29. Imperato-McGinley. Zhu JYS. Androgens and male physiology - The syndrome of 5α-reductase-2 deficiency. Mol Cell Endocrinol. 2002;198:51-9.
30. Amory JK. Anawalt BD. Matsumoto AM. Page ST. Bremner WJ, Wang C. Swerdloff RS. Clark RV. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008 Jun;179(6):2333-8.
31. Jacobsen SJ, Cheetham TC. Haque R. Shi JM, Loo RK. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA. 2008 Oct 8;300(14):1660-4.
32. Heidenreich A. Aus G. Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68-80.
33. Bhasin S. Bremner WJ. Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab. 1997;82:3-8.
34. Von Eckardstein and Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl. 2002;23(3):419-25.
35. Velazquez I. Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol. 2004;77(3):257-67.
36. Kim MK. Zhao H. Lee CH, Kim DD. Formulation of a reservoir-type testosterone transdermal delivery system. Int J Pharm. 2001 ;219 (1-2):51-9.
37. Wang C. Swerdloff RS, Iranmanesh A. et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2839-53.
38. Wang C, Swerdloff R. Kipnes M. Matsumoto AM. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3821-9.
39. Kelleher S, Conway AJ. Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol. 2001;55:531-6.
40. Ishak KG. Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin LiVer Dis. 1987;7(3):230-6.
41. Narayanan R. Mohler ML. Bohl CE, Miller DD. Dalton JT.Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6:e010.
42. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab. 1999;84(10):3459-62.
43. Mohler ML. Bohl CE. Jones A. Coss CC, Narayanan R, He Y, Hwang DJ. Dalton JT, Miller DD. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009 Jun 25;52(12):3597-617.
44. Chang CY, McDonnell DP. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol. 2002;16:647-60.
45. Narayanan R. Coss CC. Yepuru M. Kearbey JD. Miller DD. Dalton JT. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol. 2008;22(11):2448-65.
46. Morton RA Jr.. Barnette KG. Hancock ML. Rodriguez D, Dalton JT. Steiner MS. The use of a selective androgen receptor modulator to improve lean body mass and muscle performance in patients with cancer cachexia. The Endocrine Society's meeting, clinical trials symposium 2009:S21-1.